Sugi Predict

Sugi Predict / Compounds / SCHEMBL20190065

SCHEMBL20190065

SCHEMBL20190065

NNc1cnc(-c2ccc(OC(F)(F)F)cc2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.57
▸ ALOX5AP P20292 1/20 0.43
▸ FEN1 P39748 1/20 0.43
▸ ABL1 P00519 7/20 0.43
▸ BCR P11274 6/20 0.42
▸ SCN10A Q9Y5Y9 4/20 0.42
▸ SCN5A Q14524 4/20 0.42
▸ KCNH2 Q12809 2/20 0.42
▸ SCN1A P35498 1/20 0.42
▸ SCN9A Q15858 1/20 0.42
▸ SCN2A Q99250 1/20 0.42
▸ SCN8A Q9UQD0 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ TEK Q02763 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30448946 0.90 CYP1A2 (0.49) CYP1A2ALOX5APFEN1ABL1BCR
SCHEMBL23571203 0.85 CYP1A2 (0.57) CYP1A2ALOX5APFEN1ABL1BCR
SCHEMBL21835669 0.78 SCN5A (0.41) CYP1A2ALOX5APFEN1ABL1SCN5A
SCHEMBL21835703 0.78 CYP1A2 (0.51) CYP1A2ALOX5APFEN1ABL1BCR
SCHEMBL31733961 0.78 CYP1A2 (0.51) CYP1A2ALOX5APFEN1ABL1BCR
SCHEMBL20203902 0.77 CYP1A2 (0.71) CYP1A2ABL1BCRSCN10ASCN2A
SCHEMBL937077 0.77 NPC1 (0.46) SCN5ASCN9ANPC1RAB9A
SCHEMBL20209399 0.77 TRPA1 (0.48) CYP1A2ALOX5APFEN1ABL1SCN10A
SCHEMBL20203802 0.76 CYP1A2 (0.48) CYP1A2ALOX5APFEN1ABL1SCN10A
SCHEMBL20209397 0.76 CYP1A2 (0.45) CYP1A2ALOX5APFEN1ABL1SCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2025-05-22 — — US disclosed
US-20250145629-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2025-05-08 — — US disclosed
US-12145939-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2024-11-19 — — US disclosed
EP-4397308-A2 COMPOUNDS AND THEIR METHODS OFUSE Praxis Precision Medicines, Inc. (US) 2024-07-10 — — EP disclosed
EP-3548033-B1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2024-04-10 — — EP disclosed
US-20240043433-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2024-02-08 — — US disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 — — US disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 — — US disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 — — US disclosed
US-11767325-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2023-09-26 — — US disclosed
US-11629146-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity PRAXIS PRECISION MEDICINES, INC. (US) 2023-04-18 — — US disclosed
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 — — US disclosed
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 — — US disclosed
US-20210171530-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2021-06-10 — — US disclosed
EP-3548033-A1 COMPOUNDS AND THEIR METHODS OF USE Praxis Precision Medicines, Inc. (US) 2019-10-09 — — EP disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 — — WO disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11629146-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity SCN1A, SCN5A, SCN3A CYP1A2 2190/4885ALOX5AP 2088/4885FEN1 4764/4885
US-12145939-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators SCN1A, SCN2A, SCN5A CYP1A2 1553/4885ALOX5AP 2111/4885FEN1 4781/4885
US-20210188852-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B CYP1A2 1988/4885ALOX5AP 1626/4885FEN1 4562/4885
US-20250145629-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A CYP1A2 2873/4885ALOX5AP 1210/4885FEN1 4819/4885
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B CYP1A2 1988/4885ALOX5AP 1626/4885FEN1 4562/4885
US-20240043433-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A CYP1A2 2873/4885ALOX5AP 1210/4885FEN1 4819/4885
US-11767325-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators SCN1A, SCN2A, SCN5A CYP1A2 1403/4885ALOX5AP 2297/4885FEN1 4788/4885
US-20210171530-A1 ION CHANNEL MODULATORS SCN1A, SCN3A, SCN2A CYP1A2 2873/4885ALOX5AP 1210/4885FEN1 4819/4885
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B CYP1A2 1988/4885ALOX5AP 1626/4885FEN1 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.